The Value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, January 29, 2013

The Value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration



The Value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration

 Results

33 patients(mean age 56 years,range:28–81) were included; primary sites of disease were the cervix (n = 18), uterus (n = 8) and vagina/vulva (n = 7). AUCs for organ invasion ranged from 0.74-0.96. There was a significant association between FDG uptake metrics incorporating tumor volume (TLG and MTV) and OS (p ≤ 0.001) as well as between MTV and PFS (p = 0.001). No significant association was identified between SUVmax and OS/PFS (p = 0.604/0.652). Inter-reader agreement for organ invasion was fair to substantial (k = 0.36-0.74) and almost perfect for FDG quantification (ICC = 0.97-0.99).

Conclusion

In patients undergoing pelvic exenteration for recurrent gynecological malignancies, 18 F-FDG PET/CT is useful for preoperative assessment of disease extent. Furthermore, quantitative metrics of FDG uptake incorporating MTV serve as predictive biomarkers of progression-free and overall survival in this population.

Highlights

► 18 F-FDG PET/CT had high accuracy for the evaluation of disease extent prior to pelvic exenteration for recurrent gynecological cancer.
► Quantitative FDG uptake metrics incorporating tumor volume (total lesion glycolysis and metabolic tumor volume) are significantly associated with overall survival.
► No significant association was identified between SUVmax and overall survival.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.